Subcutaneous injection of pegbelfermin for 12 weeks in obese and T2D patients can improve dyslipidemia, increase adiponectin and reduce the N-terminal level of fibrosis biomarker type III collagen propeptide (PRO-C3) without causing changes in HbA1c (135). This evidence concerns the gene ADIPOQ and metabolic syndrome.